CVS HEALTH Corp
CVSConsumer & retailcvshealth.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 4, 2026
Next reportFebruary 8, 2027after close · forecast 1.256 $/share
Revenue
$108.40B
▲ +5.4% vs prior year YoY
Net income
$2.17B
▲ +154.6% vs prior year YoY
EPS
1.68$
▲ +153.7% vs prior year YoY
Net margin
2.0%
▲ +5.9 pp vs prior year YoY
Revenue▲ +5.4%
Margins (% of revenue)GrossOperatingNet
Net income▲ +154.6%
EPS▲ +153.7%
Financial statements
View 10-Q filed November 4, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $97.71B | $94.59B | $98.92B | $102.87B | $105.69B | $100.43B | $106.10B | $108.40B | ▲ +5.4% |
| Gross profit | $42.44B | $43.53B | $44.91B | $45.83B | $46.63B | $44.98B | $47.23B | $47.21B | ▲ +3.0% |
| Operating income | $2.37B | $3.37B | $2.38B | −$3.21B | $2.11B | $4.68B | $4.70B | $3.57B | ▲ +211.2% |
| Net income | $1.64B | $1.78B | $1.02B | −$3.98B | $2.94B | $2.94B | $2.98B | $2.17B | ▲ +154.6% |
| R&Dnever filed | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 1.41 $ | 0.80 $ | -3.13 $ | — | 2.30 $ | 2.31 $ | 1.68 $ | ▲ +153.7% |
| Margins (% of revenue) | |||||||||
| Gross | 43.4 % | 46.0 % | 45.4 % | 44.5 % | 44.1 % | 44.8 % | 44.5 % | 43.6 % | ▼ -1.0 pt |
| Operating | 2.4 % | 3.6 % | 2.4 % | -3.1 % | 2.0 % | 4.7 % | 4.4 % | 3.3 % | ▲ +6.4 pt |
| Net | 1.7 % | 1.9 % | 1.0 % | -3.9 % | 2.8 % | 2.9 % | 2.8 % | 2.0 % | ▲ +5.9 pt |
| Balance sheet | |||||||||
| Assets | $253.22B | $255.59B | $258.34B | $255.33B | $253.54B | $252.97B | $253.77B | $258.07B | ▲ +1.1% |
| Liabilities | $177.49B | $178.47B | $180.79B | $182.22B | $178.16B | $175.34B | $173.87B | $177.39B | ▼ -2.7% |
| Equity | $75.73B | $77.11B | $77.55B | $73.11B | $75.38B | $77.64B | $79.90B | $80.69B | ▲ +10.4% |
| Cash | $8.59B | $10.08B | $11.79B | $9.10B | $8.45B | $9.54B | $11.33B | $11.74B | ▲ +29.0% |
| Capital | |||||||||
| Shares outstanding | 1.26B | 1.27B | 1.27B | 1.27B | 1.27B | 1.28B | 1.28B | 1.28B | ▲ +0.8% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.